GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gland Pharma Ltd (BOM:543245) » Definitions » EV-to-FCF

Gland Pharma (BOM:543245) EV-to-FCF : (As of Mar. 04, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Gland Pharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Gland Pharma's Enterprise Value is ₹227,490 Mil. Gland Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was ₹0 Mil. Therefore, Gland Pharma's EV-to-FCF for today is .

The historical rank and industry rank for Gland Pharma's EV-to-FCF or its related term are showing as below:

BOM:543245' s EV-to-FCF Range Over the Past 10 Years
Min: 38.39   Med: 163.67   Max: 5581.32
Current: 38.39

During the past 7 years, the highest EV-to-FCF of Gland Pharma was 5581.32. The lowest was 38.39. And the median was 163.67.

BOM:543245's EV-to-FCF is ranked worse than
67.46% of 547 companies
in the Drug Manufacturers industry
Industry Median: 23.07 vs BOM:543245: 38.39

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-04), Gland Pharma's stock price is ₹1536.15. Gland Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was ₹42.760. Therefore, Gland Pharma's PE Ratio (TTM) for today is 35.92.


Gland Pharma EV-to-FCF Historical Data

The historical data trend for Gland Pharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gland Pharma EV-to-FCF Chart

Gland Pharma Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-FCF
Get a 7-Day Free Trial - 101.29 188.18 121.62 48.16

Gland Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 48.16 - - -

Competitive Comparison of Gland Pharma's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Gland Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gland Pharma's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Gland Pharma's EV-to-FCF falls into.



Gland Pharma EV-to-FCF Calculation

Gland Pharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=227489.624/0
=

Gland Pharma's current Enterprise Value is ₹227,490 Mil.
Gland Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gland Pharma  (BOM:543245) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Gland Pharma's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1536.15/42.760
=35.92

Gland Pharma's share price for today is ₹1536.15.
Gland Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹42.760.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Gland Pharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Gland Pharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Gland Pharma Business Description

Traded in Other Exchanges
Address
Plot No. 11 and 84, TSIIC Phase: IV, Pashamylaram (V), Patancheru (M), Sangareddy District, Hyderabad, TG, IND, 502307
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. The group is also involved in vast range of therapeutic categories that include Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and more - to Hormones and related Drugs, Fertility Supplements and Gnrh Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA.

Gland Pharma Headlines

No Headlines